Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.

Published

Journal Article

A goal of T-cell HIV vaccines is to define the correlation between a vaccine-induced immune response and protection from HIV infection. We conducted a phase 2 trial to determine if a canarypox vaccine candidate (vCP1452) administered with rgp120 subunit protein would "qualify" for a trial to define a correlate of efficacy. A total of 330 healthy volunteers were enrolled into 4 groups: 120 received vCP1452 alone (0, 1, 3, and 6 months), 120 received vCP1452 with 2 different regimens of rgp120 coadministration, and 90 received placebo. HIV-specific antibody responses were measured by enzyme-linked immunoassay (ELISA) and neutralizing activity. T-cell responses were measured by chromium release and interferon-gamma (IFNgamma) enzyme-linked immunospot (ELISpot) assay. Significant neutralizing antibody responses to the HIV MN strain were detected in all vaccine groups, with net responses ranging from 57% (95% confidence interval [CI]: 40% to 71%) to 94% (95% CI: 85% to 99%). Net cumulative HIV-specific CD8 IFNgamma ELISpot assay responses were 13% (95% CI: -1% to 26%) for recipients of vCP1452 alone and 16% (95% CI: 2% to 29%) for recipients of vCP1452 plus rgp120. Overall, the HIV-specific CD8 cytotoxic T lymphocyte (CTL) response was not sufficient to qualify the regimen for a subsequent trial designed to detect an immune correlate of protection requiring a minimum CD8 CTL frequency of 30%.

Full Text

Duke Authors

Cited Authors

  • Russell, ND; Graham, BS; Keefer, MC; McElrath, MJ; Self, SG; Weinhold, KJ; Montefiori, DC; Ferrari, G; Horton, H; Tomaras, GD; Gurunathan, S; Baglyos, L; Frey, SE; Mulligan, MJ; Harro, CD; Buchbinder, SP; Baden, LR; Blattner, WA; Koblin, BA; Corey, L; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network,

Published Date

  • February 2007

Published In

Volume / Issue

  • 44 / 2

Start / End Page

  • 203 - 212

PubMed ID

  • 17106277

Pubmed Central ID

  • 17106277

Electronic International Standard Serial Number (EISSN)

  • 1944-7884

International Standard Serial Number (ISSN)

  • 1525-4135

Digital Object Identifier (DOI)

  • 10.1097/01.qai.0000248356.48501.ff

Language

  • eng